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Abstract
The recently cloned human gene named ‘‘placental
immunoregulatory ferritin’’ (PLIF ) is a pregnancy-
related immunomodulator. Recombinant PLIF and its
bioactive domain C48 are immune-suppressive and
induce pronounced IL-10 production by immune cells.
PLIF is expressed in the placenta and breast cancer
cells. Blocking PLIF in pregnant mice by anti-C48 anti-
bodies inhibited placental and fetal growth and modu-
lated the cytokine network. It has been revealed that
anti-C48 treatment inhibited MCF-7 tumor growth in
nudemice.However, this significant effectwasobserved
only in those transfused with human peripheral blood
mononuclear cells. Blocking PLIF in tumor-engrafted
human immune cell transfusedmice resulted inmassive
infiltration of human CD45+ cells (mainly CD8+ T cells),
both intratumorally and in the tumor periphery, and a
significant number of caspase-3+ cells. In vitro, anti-
C48 treatment of MCF-7 tumor cells cocultured with
human lymphocytes induced a significant increase in
interferon-; secretion. We conclude that blocking PLIF
inhibits breast cancer growth, possibly by an effect on
the cytokine network in immune cells and on break-
down of immunosuppression.
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Introduction
It is now accepted that the immune system can mediate the
suppression of tumor growth in cancer-bearing patients.
Target antigens have been identified, and cancer vaccines
have been developed using mostly immunogenes that can
prime T cells and immune responses that lead to destruc-
tion of tumor cells in animal models [1]. However, many of
the responses are partial and transient. Tumor cells may
employ immunosuppressive mechanisms resembling those
in the placenta, which are believed to prevent rejection of
the embryo [2,3].
In recent years, our group has reported the cloning and
characterization of a novel human pregnancy–related im-
mune modulator named ‘‘placental immunoregulatory fer-
ritin’’ (PLIF). PLIF cDNA was isolated from human placenta
cDNA library [4]. It has a unique molecular structure composed
of an incomplete ferritin heavy-chain sequence (amino acids
1–117) linked to a novel nonferritin 48–amino acid domain
named C48 (amino acids 118–165). PLIF is expressed in
placental syncytiotrophoblast cells and decidual mononuclear
cells [4]. PLIF codes for the unique p43 subunit of placental
isoferritin (PLF), which has been previously identified using its
specific monoclonal antibody (MoAb) CM-H9 [5,6]. The molec-
ular mass of p43 is 43 kDa, and it represents a molecular dimer
of PLIF (molecular mass, 22 kDa).
Accumulated data revealed that PLIF acts as an immuno-
suppressive cytokine and that C48 represents its bioactive
domain [4]. The in vitro and in vivo regulatory functions of PLIF
are not dependent on any ferritin sequence [4]. The functions of
PLIF, as well as of its subcloned C48 fragment, were partially
attributed to the induction of pronounced and rapid IL-10 produc-
tion, as well as of granulocyte–macrophage colony-stimulating
factor and IL-6, and to the modulation of cytokine–chemokine
networks in immune cells [7,8]. This was demonstrated in vitro
in peripheral blood mononuclear cells (PBMCs) [4,5] and in
human bonemarrow cells [8], as well as in vivo in animal models
of rheumatoid arthritis [9].
The expression of PLIF in the placenta is associated with
prevention of embryo rejection [10,11]. Indeed, blocking PLIF in
pregnant mice by in vivo treatment with anti-C48 antibodies
affected placental development and resulted in fetal growth re-
tardation and resorption accompanied bymodulation of the cyto-
kine network fromT helper (Th) 2 response to Th1 response [12].
In pathological conditions, PLIF has been shown to be
expressed in malignant diseases such as lymphoproliferative
diseases [13], in human breast cancer tissues, and in PBMCs
[14] and breast cancer cell lines (T47D and MCF-7) [4], but not
in benign breast disease [15]. Thus, expression of PLIF, similar
to its function in the embryo, could manipulate the cytokine
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network and immune response in the tumor microenviron-
ment and could enable tumor immune escape and growth.
Accordingly, the aim of the current study was to investi-
gate whether in vivo blocking of PLIF in human breast cancer
by treatment with anti–PLIF/C48 antibodies in a nudemouse
model would affect tumor development and whether it is
immune cell–dependent.
Materials and Methods
Prokaryotic Protein Expression and Purification of C48
The cDNA fragment coding for the 48–amino acid
C-terminal (C48) of PLIF was subcloned into a pGEX 5X-1
prokaryotic expression vector (Amersham Biosciences, Pis-
cataway, NJ) resulting in a glutathione-S-transferase (GST)–
C48 fusion vector, as previously described [4]. This vector
was transformed into Escherichia coli BL-21 strain. Bacterial
cultures of transformants were harvested after induction with
isopropylthiogalactoside and lysed in Triton X-100–based
lysis buffer. Then fusion protein was absorbed from lysates
using Glutathione Sepharose 4B beads and subsequently
eluted (GE Healthcare, Bucks, UK) with an excess of free
glutathione. After dialysis, factor Xa cleaved the fusion pro-
tein, and purified C48 was obtained by removal of the cleaved
GST part using Glutathione Sepharose beads.
Control GST protein was prepared by using the empty
pGEX 5X-1 expression vector transformed into E. coli BL-21
strain, as described above.
Preparation of Rabbit Anti-C48 Immunoglobulin (Ig)
Rabbits were immunized with purified recombinant C48 or
with GST and control anti-GST Ig [11]. Each rabbit was
immunized with 50 mg of purified protein mixed (vol/vol) with
complete Freund’s adjuvant on days 1, 7, and 21. On day 28,
rabbits were bled, and Igs were isolated from anti-C48 and
anti-GST sera by salt precipitation. Control Igs from pre-
immunized rabbits were also purified. Endotoxin levels in
purified anti-C48 Ig and anti-GST Ig preparations used for
treatment were < 0.1 EU/mg protein. This was determined by
the Limulus amebocyte lysate assay (Biological Industries,
Beit Haemek, Israel).
The specificity of anti-C48 Ig was tested on breast cell
lines. It was revealed that C48 Ig does not react with cells
derived from a normal lactating breast (HBL-100), but reacts
with breast cancer cell lines T47D and MCF-7, which express
PLIF [4]. Anti-C48 Ig reacts by Western blot analysis with
C48 and PLIF [4], but does not react with ferritin H chain
(unpublished results). Anti-C48 reacts by enzyme-linked
immunosorbent assay (ELISA) with sera from pregnant
women (unpublished results) and sera from pregnant mice
[12], but does not react with normal human sera (unpublished)
and normal mouse sera [12].
Cell Cultures
The MCF-7 human breast carcinoma cell line was main-
tained in monolayer cultures in RPMI 1640 medium supple-
mented with 10% fetal calf serum. For passages, confluent
monolayer cultures were trypsinized with trypsin/EDTA solu-
tion (0.25%/0.05%, respectively), washed once, and seeded
in culture medium.
Preparation of Human PBMCs
Buffy coats from blood bank donors were layered onto
Lymphoprep solution (Nycomed, Oslo, Norway) and spun at
2000 rpm for 20 minutes. The interface layer was collected,
washed twice, counted, and resuspended in phosphate-
buffered saline (PBS; pH 7.4) to the desired cell concentration.
MCF-7 and PBMC Coculture
TrypsinizedMCF-7 cells were seeded into six-well plates at
4  105 cells/well and incubated for 1 hour in a 5% CO2
incubator. Furthermore, supernatants containing nonadherent
cells were removed and replaced with fresh medium contain-
ing PBMCs at 4  106 cells/well at a final volume of 2 ml.
Antibodies (100 mg/ml) were added daily to the coculture with
MCF-7 cells. The supernatants were collected at 24, 48, and
72 hours of culture, centrifuged at 500g for 10 minutes to
remove nonadherent cells, and frozen at 20jC.
MCF-7 monolayer was washed twice with PBS and fixed
for 1 hour with 4% paraformaldehyde solution for micro-
scopic visualization.
Measurement of Cytokine Production By ELISA
ELISA kits for the human cytokines IL-10 and interferon-g
(IFN-g) were purchased from DPC (Sigma, St. Louis, MO)
and Peprotec Systems USA (Rocky Hill, NJ). These kits
were used according to the manufacturer’s instructions to
quantify indicated cytokines produced in the supernatants.
In Vivo Studies
The study was approved by the animal review board of
the Sackler School of Medicine, Tel Aviv University (Petah
Tiqwa, Israel).
Athymic nude mice were purchased from Harlan Labora-
tories, Ltd. (Jerusalem, Israel). Mice were inoculated sub-
cutaneously with MCF-7 human breast cancer cells (6  106)
in the presence of an estrogen source from 0.72 mg of
b-estradiol pellets (Innovative Research of America, Sarasota,
FL). Slow-release pellets (60-day release) were implanted
subcutaneously into the cervical scapular space. Human
PBMCs (40  106/0.5 ml) were injected intravenously after
the transplantation of MCF-7 tumor cells, as described above.
Treatment of Tumor-Bearing Mice with Anti-C48 Ig
In each experiment, mice were divided into groups of six
mice. Anti–recombinant C48 Ig (anti-C48 Ig) was injected
intraperitoneally to each mouse daily at an optimal dose of
2 mg/0.3 ml, as previously determined [11]. Control mice
received daily injections of rabbit anti-GST Ig (control Ig) for
nonspecific cytotoxic and cytopatic effects of rabbit Ig. Mice
were sacrificed as indicated in Results.
Gross and Microscopic Pathology
Tumors were excised 20 days after tumor cell inoculation.
They were measured by caliper measurements (using the
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formula: length  length), weighed, and fixed in phosphate-
buffered formalin (pH 7.0) from which paraffin-embedded
blocks were prepared.
Immunohistochemistry
Four-micron tissue sections were cut from paraffin-
embedded blocks and mounted on coated Superfrost Plus
slides (Electron Microscopy Sciences, Hatfield, PA). They
were deparaffinized in xylene, rehydrated with graded alco-
hols, rinsed in H2O, incubated in 3% H2O2 for 10 minutes,
and washed in H2O.
For antigen unmasking, the sections were heated in
10 mM sodium citrate buffer (pH 6.0) for 10 minutes in a
microwave or pressure chamber, depending on the manu-
facturer’s instructions, and then they were cooled at room
temperature for 20 minutes. Slides were washed in H2O
and PBS buffer for 5 minutes.
Slides were incubated in normal serum for 10 minutes
with a kit (Zymed Laboratories, San Francisco, CA).
For immunohistochemical staining performed manually,
slides were incubated with primary antibodies at previously
determined optimal concentrations for 60 minutes at room
temperature (Table 1).
Slides were washed in H2O and PBS buffer for 5 minutes
and further incubated for 10 minutes with biotinylated second
antibody (Zymed Laboratories) followed by PBS.
Slides were further incubated for 10 minutes with conju-
gated streptavidin horseradish peroxidase (Zymed Laborato-
ries), washed with PBS, incubated with 3,3V-diaminobenzidine
(Zymed Laboratories) for 5 minutes, and further washed with
PBS. Stained slides were counterstained with Mayer’s hema-
toxylin and mounted with aqueous mounting solution.
Counting Procedure for Immunohistochemical Analysis
Immunohistochemistry results were obtained by counting
the number of positively stained cells for each immuno-
histochemical stain.
Positive cells were counted in two areas: between tumoral
cells and in the periphery of the tumor surrounded by a thin
fibrous capsule and fat tissues.
We selected three areas for each stain: themost positively
stained area and two other randomly stained areas. Stained
cells appear to have brown cytoplasm. Counting areas were
covered with a cover slip on which a 4-mm2 square was
marked [16]. We counted positive cells within this square at
400 magnification, and the results of three such squares
were calculated as mean positive cells/4 mm2  3 and ex-
pressed as the mean percentage of positive cells in the
marked area for all antibodies. For CD4 and CD8 cells, the
ratio was indicated as the percentage of positive lymphocytes
detected by LCA.
Statistical Analysis
Results were presented as mean ± standard deviation.
Comparisons were made by Student’s t test. P V .05 was
considered statistically significant.
Results
Effect of Therapeutic Anti-C48 Ig on MCF-7 Tumor
Development in Nude Mice
The functional role of PLIF in tumor development was
studied in a human breast cancer animal model. Nude mice
were implanted subcutaneously with MCF-7 tumor cells,
followed by daily intraperitoneal injections with anti-C48 Ig
(2 mg) to block PLIF activity. Control mice received anti-GST
Ig (2 mg) for comparison (control Ig).
After 20 days, the mice were sacrificed, and the tumors
were removed and measured. As seen in Figure 1a, there
Table 1. Antibody Specificity By Immunohistochemical Staining.
Positive
Control
Origin Cellular
Distribution
Antibody
Tonsil Biogenex, San Ramon, CA All leukocytes LCA
Tonsil Zymed Laboratories T cells (helper) CD4
Tonsil Signet, Dedham, MA T cells (suppressor) CD8
Tonsil Zymed Laboratories B cells CD20
Tonsil Cell Signaling Technology,
Beverly, MA
Apoptotic cells Caspase-3
Tonsil R&D Systems, Minneapolis, MN IL-10
Tonsil R&D Systems IFN-g
Figure 1. The effect of anti-C48 Ig treatment without and with inoculated PBMC
on the growth of MCF-7 breast tumors in nude mice. (a) Nude mice without
PBMC inoculation. (b) Nude mice inoculated intravenously with human PBMCs
(40 106/0.5 ml) (HICT) after the engraftment of MCF-7 breast cancer cells. All
mice received daily intraperitoneal injections of anti-C48 Ig or control Ig (2 mg/
0.3 ml). Bars represent mean ± S.E. (n = 6).
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was no significant difference between the mean size of tu-
mors removed from the anti–C48 Ig–treated group (58.6 ±
12 mm2) and the mean size of tumors removed from the
control group (41.3 ± 3 mm2) (P = .27) (Figure 1a). These
results indicated that there was no direct effect of anti-C48
antibodies on the growth and development of MCF-7 human
breast cancer cells.
Because PLIF is an immunosuppressive regulator that
affects the cytokine network in immune cells, we investigated
whether, in the nude mouse model, passive transfer of
lymphocytes and blocking of PLIF in MCF-7 tumor cells af-
fect tumor growth.
In the following experiments, human PBMCs were in-
jected intravenously to MCF-7–engrafted nude mice, and
the mice were treated as described above. As seen in Fig-
ures 1b and 2A, in human immune cell transfused (HICT)
mice, treatment with anti-C48 Ig significantly inhibited the
growth of tumors (5.6 ± 3.6 mm2) compared with mice
treated with control Ig (68.5 ± 23.9 mm2) (P = .005).
Furthermore, in MCF-7–engrafted HICT mice, treatment
with anti-C48 Ig on days 1 to 30 after tumor engraftment
prolonged their survival compared with control HICT mice.
After 45 days, 100% of the mice treated with anti-C48 Ig
were alive compared with only 20% in the control Ig–treated
group (Figure 3).
Immunohistochemical Characterization
By staining with hematoxylin and eosin, there were large
areas of tumoral necrosis in tumors removed from anti–C48
Ig–treated mice. In comparison, tumors removed from con-
trol Ig–treated mice showed nearly no necrosis.
Immunohistochemical analyses of tumors derived from
HICT mice treated with anti-C48 Ig and control Ig are pre-
sented in Figure 2.
Figure 2. Gross and microscopic immunohistochemical analyses of tumors removed from HICT mice treated with anti-C48 Ig (A2, C, E, and G) or control Ig (A1, B,
D, and F). (A) Tumor size. (B and C) CD45+ inside tumors. (D and E) CD45+ in tumors. (F and G) Caspase-3+.
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Phenotypic analysis of tumor-infiltrating leukocytes was
carried out with the following MoAbs: anti-CD45, anti-CD4,
anti-CD8, and anti-CD20. Figure 2 shows images obtained
from representative tumors.
As seen in Figures 2C and 4, specimen obtained from the
anti–C48 Ig–treated group exhibited massive infiltration
of human CD45+ cells between tumor cells (mean/4 mm2 =
40 ± 1%) and in the tumor periphery (25 ± 3%) (Figure 4). In
comparison, specimens obtained from the control Ig–treated
group (Figure 2B) exhibited very low leukocyte infiltration
either intratumorally (2.6 ± 0.7%) or in the tumor periphery
(4.1 ± 0.5%) (Figure 4).
Furthermore, immunophenotyping with anti-CD4, anti-
CD8, and anti-CD20 revealed that the majority of CD45+
cells were T lymphocytes (Figure 5), whereas only few
stained B cells (CD20+) could be seen (not shown). Further-
more, most of those infiltrating the tumors derived from
anti–C48 Ig–treated mice were CD8+ (Figure 5). A compar-
ison of infiltrating T-cell subsets in the periphery of tumors
removed from anti-C48 Ig and those from control Ig–treated
mice revealed a reversed ratio of CD4+/CD8+ cells (Figure 5).
Whereas the CD4/CD8 ratio in control Ig–treated tumors
was 1.39, the ratio in anti–C48 Ig–treated tumors was
0.4 (Figure 5).
Functional Immune Characterization
Immunohistochemical analyses of cytokines with anti-
bodies to INF-g and IL-10 did not yield a positive staining
of tumor sections. Yet, immunostaining of apoptotic cells with
anti–caspase-3 antibodies exhibited positive staining. A
difference in the proportion of positively stained apoptotic
cells was observed between tumors from anti–C48 Ig–
treated mice and tumors from control Ig–treated mice (Fig-
ure 2, F andG). The mean numbers of caspase-3+ cells were
significantly increased intratumorally (40 ± 1) and in the
tumor periphery (25 ± 3) of anti–C48 Ig–treated tumors
compared with control Ig–treated tumors (20 ± 3 and 6.6 ± 2,
respectively) (Figure 6).
Figure 4. Quantitative immunohistochemical analysis of human leukocytes
(CD45+) infiltrating MCF-7 human breast tumors removed from HICT nude
mice treated with anti-C48 Ig and control Ig. Data are expressed as the mean
percentage of positive cells in area section (4 mm2) ± S.E. (n = 3) (as in
Materials and Methods).
Figure 3. The effect of anti-C48 Ig treatment on the survival of MCF-7 tumor-
bearing HICT nude mice. Mice engrafted as in Figure 1 were treated daily
(1–30 days) with anti-C48 Ig or control Ig (2 mg/0.3 ml, i.p.) and followed
up for 45 days.
Figure 5. Quantitative immunohistochemical analysis of human CD4 and
CD8 T cells infiltrating human breast tumors removed from HITC nude mice
treated with anti-C48 Ig and control Ig. Data are expressed as the mean
proportion of CD45+ cells in area section (4 mm2) ± S.E. (n = 3).
Figure 6. Quantitative immunohistochemical analysis of caspase-3+ cells in
human breast tumors removed from HITC nude mice treated with anti-C48 Ig
and control Ig. Data are expressed as the mean percentage of positive cells in
area (4 mm2) ± S.E. (n = 3).
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IFN-c and IL-10 Secretion in Cocultures of MCF-7
and PBMCs Treated In Vitro with Anti-C48 Ig
Because we could not demonstrate the immunostaining
of cytokines (IL-10 or INF-g) in sections of tumors removed
from HICT mice treated in vivo with either anti-C48 Ig or
control Ig, an attempt was made to investigate the effect of
this treatment on cytokine secretion in vitro.
These experiments were carried out in cocultures of
MCF-7 breast cancer cells and PBMCs from three healthy
blood bank donors treated in vitro daily with anti-C48 Ig or
control Ig. Amounts of INF-g and IL-10 that accumulated
during 24, 48, and 72 hours were measured in the super-
natants of these cocultures.
The results of a representative experiment are presented
in Figures 7 and 8.
The level of INF-g was measured in the following cell
cultures: PBMC; PBMC + MCF-7 cells; PBMC + MCF-7 cells
treated daily with control Ig (100 mg/ml); PBMC +MCF-7 cells
treated daily with anti-C48 Ig (100 mg/ml). As seen in a
representative experiment (Figure 7), a marked increase in
Figure 7. Time course secretion of INF-c in mixed cultures of MCF-7 cells and PBMCs (2  106 ml1) treated daily with anti-C48 Ig or control Ig (100 l). Culture
supernatants were removed at 24, 48, and 72 hours of incubation and centrifuged at 500g for 10 minutes to remove cells and debris, and the supernatant (100 g/ml)
was subjected to an ELISA plate for quantitative measurement of INF-c (a representative experiment).
Figure 8. Time course secretion of IL-10 in mixed cultures of MCF-7 cells and PBMCs (106 ml1) treated daily with anti-C48 Ig or control Ig (100 g/ml).
Supernatants were collected as in Figure 7 and subjected (100 l) to an ELISA plate for quantitative measurement of IL-10 (a representative experiment).
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INF-g (540 mg/ml) was measured after 24 hours of incuba-
tion in cocultures of PBMCs and MCF-7 cells treated with
anti-C48 Ig. This is compared with the level in the following
control cultures: PBMC (0 pg/ml); PBMC + MCF-7 cells (135
pg/ml); PBMC + MCF-7 cells treated with control Ig (240 pg/
ml). INF-g level accumulated further at 72 hours up to 780
pg/ml in anti–C48 Ig–treated cultures, and proportionally
lower levels were measured in control cultures (Figure 7).
Measurements of IL-10 level in the respective cultures did
not reveal a significant difference between them, and no
accumulation of IL-10 was measured following further incu-
bation time for 72 hours (Figure 8). It is noteworthy that
treatment of PBMC cultures with anti-C48 Ig or control Ig did
not affect the levels of INF-g and IL-10 compared to non-
treated PBMC cultures (not shown).
Discussion
In the present study, we analyzed different immunologic
parameters associated with human breast tumors following
treatment with antibodies to C48 (PLIF), a tumor-associated
immunosuppressive protein.
The results demonstrated that treatment with anti-C48
(PLIF) antibodies significantly inhibited tumor growth and
increased host survival. This was not a direct antitumor effect
of anti-C48 (PLIF) antibodies, but was rather mediated by
transfused human PBMCs into nude mice.
Furthermore, it was found that the anti-C48 (PLIF) treat-
ment of tumor-engrafted HICT mice resulted in large necrotic
areas and massive infiltration of human leukocytes (CD45+)
intratumorally and in the tumor periphery, as opposed to lack
of infiltration in control Ig–treated tumors. Most of the tumor-
infiltrating leukocytes were T cells, and the majority were
CD8+ (reversed CD4/CD8 ratio).
Despite the interest in immune prevention strategies,
information on molecular events associated with prevention
of tumor development is scarce. Our results may be ana-
lyzed in line with current views.
The presence of tumor-infiltrating leukocytes in residual
tumors removed from C48-treated mice may indicate a
tumor-related immune response [17]. Furthermore, the large
necrotic areas induced by this treatment may possibly re-
sult in successful self-antitumor immunization if located in
the correct cytokine environment, as has been previously
suggested [18].
It was suggested that the cytokine profile of the tumor
microenvironment may modulate tumor–host interaction.
Hence, cytokine deregulation is likely to participate in the
development or evolution of the malignant process [19].
It is noteworthy that IL-10 suppresses the function of
antigen-presenting cells and T cells by inhibiting proinflam-
matory cytokine production. A role for IL-10 in the pathogen-
esis of cancer has been demonstrated by potent therapeutic
antitumor effects of anti– IL-10 receptor MoAbs combined
with anti–Toll-like receptor-9 [20].
Indeed, C48 (PLIF) is an inducer of IL-10 production and
regulator of cytokine–chemokine networks in immunocytes
[4,7,8]. It is expressed in MCF-7 cells and in the cytosol of
human breast cancer tissue, where its level correlates with
features of tumor cell differentiation [21]. Furthermore, PLIF
is expressed on the surface of breast cancer cells [22], on the
surface of PBMCs from breast cancer patients [15], and in
the blood of patients with breast cancer [23]. Breast cancer–
associated PLF downregulates lymphocyte mitogenesis
[24], and activated lymphocytes from breast cancer patients
express characteristics of Th2 cells [25].
Our working hypothesis suggests that PLIF expressed
by syncytiotrophoblast cells in the feto-maternal interface
or, alternatively, by breast cancer cells interacting with im-
mune cells activates a Th2 response resulting in immuno-
suppression. Blocking this effect may tip the balance
toward TH1 response and subsequent abortion or tumor re-
jection, respectively.
In a previous study, we have demonstrated that block-
ing PLIF in pregnant mice by treatment with anti-C48 anti-
bodies affected placental and fetal growth in inbred and
outbred allogeneic pregnancies, resulting in a high ratio of
embryo resorption and diminished placental growth [12].
This effect was associated with an increased secretion of
Th1 cytokines (IL-2, TNF, and IL-12) and a decrease in Th2
cytokines (IL-4, IL-5, IL-10, and IL-6) compared with normal
outcome pregnancies.
In the current study, we could not demonstrate by immuno-
histochemical staining the expression of either human IL-10
(Th2) or INF-g (Th1) in cytokine sections of tumors from HICT
mice. Yet the in vitro experiments carried out in cocultures of
MCF-7 cells and PBMCs revealed that blocking PLIF by anti-
C48 Ig treatment induced a significant increase in INF-g
secretion (Th1 cytokine) compared with control cultures, but
without affecting IL-10 production.
Previously, it has been shown that INF-g induced in MCF-
7 breast adenocarcinoma cells induces the expression of
functional FasL, which is a major effector molecule used by
CD8+ cytotoxic lymphocytes to kill target cells [26]. Further-
more, INF-g has been shown to upregulate caspase-3 in
MCF-7 breast cancer cells and to sensitize these cells to
death receptor–mediated apoptosis [27,28].
The high ratio of human CD8 cells infiltrating tumors
in anti–C48-treated mice and the significantly higher number
of caspase-3+ cells in these tumors may indicate a mecha-
nism of cytotoxicity and apoptosis mediated by infused
human PBMCs.
Moreover, the current results, together with previous
findings [7–9,12], suggest that modulation of cytokine profile
following anti-C48 treatment affected tumor–host inter-
action, resulting in tumor rejection. This is in agreement with
the findings of Gong et al. [29] in their study of T cells from
patients with prostate cancer.
Hopefully, these results might guide the application of
PLIF blockade by anti-C48 as a therapeutic approach in
subgroups of human tumors that express the immuno-
suppressive PLIF protein.
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